ABSTRACT
INTRODUCTION
P63, a selective histochemical marker of basal/stem cells of stratified epithelium and of myoepithelial cells 1 , is a p53 homologue which plays an essential role in both morphogenesis of the epidermis and limb development 2 . Recently 3 , it has been shown that p63 is required for p53-dependent apoptosis in response to DNA damage.
Structurally, the p63 gene is located on chromosome 3q27-29 4 and encodes three isoforms, p63α, p63β and p63γ, which share a common amino-terminal end but differ at their carboxyl-terminal ends due to alternate mRNA splicings 5 . In addition, the gene for p63 contains a second promoter located upstream of exon 3, which gives rise to three amino-terminal deleted (p63ΔΝ) transcripts. The deleted amino-terminal region codes for a domain that is capable of trans-activating p53 target genes, including those involved in apoptosis. Consequently, p63ΔΝ isoforms lack p53-like activity. However, because they maintain their ability to compete with p53 for DNA target sites, p63ΔΝ isoforms appear to negatively regulate p53 activity 6 . These isoforms are the predominant type found in epithelial stem cells.
The key role of p63 in embryogenesis has been demonstrated by knock out experiments in mice 7 . p63-deficient mice exhibit truncated forelimbs, absent hind limbs, absence of teeth, hair follicles and mammary glands. In p63-deficient mice, the oral epithelium consists of only a single layer of flattened epithelial cells 7 . It appears that these deficiencies are caused by a perturbation of ectodermal-mesenchymal signaling, likely due to a lack of stem cells necessary to sustain epithelial morphogenesis and renewal 8 . In the absence of p63 expression, the basal cells undergo terminal differentiation, effectively running out of stem cells. It has been hypothesized that the preferential expression of the transactivation-deficient p63ΔΝ isoforms protects the basal epithelial cells from p53-induced apoptosis 6 .
In humans, p63 gene mutations are involved in the pathogenesis of at least five autosomal dominantly inherited syndromes characterized by various combinations of limb deformities 9, 10 . The most common of these is ectrodactily, ectodermal dysplasia and facial clefts syndrome (EEC), which closely resembles the phenotype seen in p63-deficient homozygous mice 5 .
At the cellular level, p63 is constitutively expressed in the basal cell nuclei of many normal stratified epithelial tissues 6 , including skin, squamous epithelium of the oral cavity, esophagus and cervix, prostatic acinar basal cells, esophageal mucosal gland ducts, and urothelium. P63 is strongly expressed in breast myoepithelial cells 11 and is also expressed in normal thymus and in thymomas 13 . P63 expression is not found in the basal non-stratified epithelium of the stomach, colon or small intestine 12 , nor is it detected in normal mesenchymal or neural/neuroendocrine tissue 13 .
Myofibroblasts are consistently negative for p63. This is in contrast to other myoepithelial markers such as calponin and smooth muscle actin, which can show variable myofibroblastic staining.
Barbareschi et al 11 identified a small subset of p63 positive, alpha-smooth muscle actin negative basal cells in the human breast, which may represent the breast somatic stem cell.
A direct role for p63 in tumorogenesis has not been demonstrated to date, although amplification of the 3q27 region has been seen in a number of tumors, including squamous cell carcinoma 4 . This is suggestive of a putative role as an oncogene rather than as a tumor suppressor gene 6 .
In neoplastic tissue, p63 immunoreactivity has been demonstrated in squamous cell and urothelial carcinomas 14 , whereas it is generally absent in most non-squamous cell carcinomas 11 . Adenocarcinomas reportedly do not express p63 13 .
This loss of immunoreactivity in non-squamous cell malignant neoplasms has been exploited to aid in identifying microinvasion in cases of DCIS and LCIS 11 , and to differentiate benign prostatic tissue from adenocarcinoma [14] [15] . In the case of poorly differentiated metastatic carcinomas, positive immunostaining for both p63 and CK5/6 is highly predictive of a primary tumor of squamous epithelial origin 14 .
To date, no in depth studies on the expression of p63 in malignant head and neck The purpose of this study was to compare the extent of p63 immunoreactivity in adenoid cystic carcinoma, polymorphous low-grade adenocarcinoma and monomorphic adenoma. The H&E stained slides were independently reviewed by two experienced pathologists (RK, TB) and agreement was reached on all cases included in this study using accepted criteria 17 .
MATERIALS AND METHODS

Formalin
Microwave heat-induced epitope retrieval (750 W microwave at medium power, 30 minutes) was performed using the Trilogy™ system (Cell Marque, Hot Springs AK)
as per the manufacturer's directions and then treated with anti-human p63 monoclonal antibody that detects all isoforms (Ab-4, clones 4A4 and Y4A3; Neomarkers, Fremont CA) at a 1:50 dilution.
The antibody-antigen complex was detected using an indirect biotin-avidin system as per the manufacturer's instructions (Ventana Basic DAB Detection Kit™, Ventana Medical Systems, Tucson AZ).
Fetal adrenal cortex was used as positive control. Normal salivary gland tissue was used as the negative control. When present, stratified squamous epithelium was used as an internal positive control.
Immunoreactivity was independently assessed by all study participants.
Agreement was reached on all 49 specimens examined. Immunoreactivity was considered positive if greater than 10% of the tumor cells stained and was graded as weak (10-25%), mild (26-50%), moderate (51-75%) and strong (76-100%).
RESULTS
The ACC group, comprising 12 women and 3 men, had a median age of 65 years The monomorphic adenomas variably expressed the p63 antigen (6/17, 35%).
Subdividing the monomorphic adenomas (Table 2 ) demonstrated no staining in the canalicular adeoma subtype (Figure 3a ) and variable staining in the basal cell adenomas (Figure 3b ). All basal cell adenomas of parotid origin stained strongly positive for p63.
Staining was localized to the peripheral tumor cells located adjacent to the connective tissue stroma. None of the basal cell adenomas from the upper lip stained for p63.
In the normal surrounding salivary gland tissue, immunoreactivity was focally detected in the basal cells of striated ducts. We were unable to demonstrate any p63 staining in the canalicular adenomas. Positive p63 reactivity was also identified in the majority of ACCs.
Monomorphic adenomas variably expressed the p63 antigen, with the canalicular adenomas demonstrating no staining and the basal cell adenomas of parotid gland origin exhibiting strong staining. In the normal surrounding salivary gland tissue, p63 reactivity was identified only focally in basal cells of striated ducts.
In summary, we find that p63 does not appear to be an ideal marker for distinguishing between ACC and PLGA in equivocal cases, or benign from malignant salivary gland neoplasms. 
